Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | EDNRB | P24530 | 2/20 | 0.34 |
| ▸ | EDNRA | P25101 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10408209 | 0.88 | SKP2 (0.50) | SKP2KDM4EGLAMAPTNPC1 | |
| SCHEMBL10408038 | 0.86 | SKP2 (0.44) | SKP2MAPTNPC1LMNARAB9A | |
| SCHEMBL10407964 | 0.85 | SKP2 (0.43) | SKP2MAPTNPC1LMNARAB9A | |
| SCHEMBL28110905 | 0.85 | SKP2 (0.43) | SKP2MAPTNPC1LMNARAB9A | |
| SCHEMBL19829362 | 0.85 | SKP2 (0.43) | SKP2MAPTNPC1LMNARAB9A | |
| SCHEMBL4437659 | 0.83 | EDNRB (0.37) | SKP2KDM4EGLAMAPTMEN1 | |
| SCHEMBL382588 | 0.83 | MAPT (0.47) | KDM4EGLAMAPTNPC1LMNA | |
| SCHEMBL2015922 | 0.81 | HTR2A (0.49) | KDM4EGLAMAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4763076 | 0.81 | MAPT (0.46) | KDM4EGLAMAPTNPC1LMNA | |
| SCHEMBL31413498 | 0.81 | HTR2A (0.49) | KDM4EGLAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8476268-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| WO-2012152983-A1 | PHENYL- SULFONYL DERIVATIVES AS MEDIATORS OF TRPA1 RECEPTOR ACTIVITY FOR THE TREATMENT OF PAIN | ORION CORPORATION (FI) | 2012-11-15 | — | — | WO | disclosed |
| EP-2520566-A1 | New Pharmaceutical Compounds | Orion Corporation (FI) | 2012-11-07 | — | — | EP | disclosed |
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| US-4925984-A | REACTION WITH BROMINE IN SOLUTION | ETHYL CORPORATION (US) | 1990-05-15 | — | — | US | disclosed |
| US-3948950-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3942972-A | Dioxolane substituted α-haloanilides as herbicides | VELSICOL CHEMICAL CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
| US-3940259-A | Dioxane substituted-α-haloanilides as herbicides | VELSICOL CHEMICAL CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | SKP2 1009/4885KDM4E 1306/4885GLA 2237/4885 |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | SKP2 1009/4885KDM4E 1306/4885GLA 2237/4885 |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | SKP2 653/4885KDM4E 1062/4885GLA 1504/4885 |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | AAK1, NCK1, DAPK2 | SKP2 250/4885KDM4E 1264/4885GLA 4627/4885 |
| US-10035777-B2 | Heterocyclic kinase inhibitors | AAK1, NCK1, DAPK2 | SKP2 250/4885KDM4E 1264/4885GLA 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.